The smaller the effect of vaccine on progression to disease, the more closely VE-acq can predict VE-disease (see Fig. 1). The consideration of NP carriage as part of the licensure pathway emerged from the need for a MDV3100 solubility dmso more direct measurement of vaccine efficacy to evaluate non-conjugate vaccines, new dosing schedules, expanded serotype coverage

and impact in varied geographic and epidemiological settings. Described by Professor David Goldblatt and Dr. Debby Bogaerts, there are advantages and disadvantages to the inclusion of NP carriage as a surrogate for disease protection in vaccine trials. NP carriage can serve as a functional biological assay that is relatively

easy to measure and that has a high negative predictive value of an individual’s risk for pneumococcal disease. VE-col also provides information about the population-level impact of vaccination because if there is no carriage, there is no risk of transmission of pneumococcus, and thus carriage prevention predicts the indirect effect of vaccine Selleck Androgen Receptor Antagonist introduction. Since NP carriage of pneumococcus is a more common outcome than disease endpoints, vaccine trials looking at carriage can be powered with smaller sample sizes. Some drawbacks to considering NP carriage data in vaccine trials include low positive predictive value of NP carriage as a surrogate marker for disease: not all serotypes causing IPD are detected regularly in NP sampling (e.g. serotypes 1 and 5) and not all carried serotypes are significant causes

of disease. Pneumococcal NP carriage itself is a dynamic event that is influenced by competing NP flora, immune fitness of the host, and density of colonization. These factors may present real differences in an individual’s risk for disease in a clinical trial setting. Adenylyl cyclase Finally, there are potential confounders in a clinical study of NP carriage that need to be considered a priori such as antibiotic use and the impact of breastfeeding. The implications for the pneumococcal licensure pathway – in fact for the licensure pathway for any vaccine based on a carrier state – involve advantages and disadvantages. Taking the potential pros and cons into account (summarized in Table 2), the use of NP carriage data as supporting evidence in the vaccine licensure pathway for those products with an articulated licensure mechanism is most likely to be least contentious as a way forward. At the start of the second day of the consultation, two specific questions were posed to vaccine manufacturers and regulators: (1) are there different approaches based on the pneumococcal vaccine product type to be licensed, e.g.